Drug Trial Radar · NCT06769126
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
Last checked: Nov 19, 2026Latest source record: Mar 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
900
Planned (sponsor's estimate)
Start
Nov 6, 2025
Primary completion
Dec 31, 2028
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- SWOG Cancer Research NetworkResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Jan 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial tests how well biomarker tests on patients tumor tissue works in selecting personalized treatments for patients with extensive stage small cell lung cancer (ES-SCLC). Biomarker tests look for certain features in cancer cells that may give doctors more information about what is driving cancer and how to treat it. Based on the biomarker test results, study doctors can determine the subtype of ES-SCLC that study treatments can target. This study also tests different types of maintenance treatment for ES-SCLC with drugs durvalumab, saruparib, ceralasertib or monalizumab. Maintenance treatment is given after initial treatment and is given to help keep the cancer under control and prevent it from getting worse. Immunotherapy with monoclonal antibodies, such as durvalumab and monalizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Saruparib is a PARP inhibitor. PARP is a protein that helps repair damaged deoxyribonucleic acid (DNA). Blocking PARP may prevent cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Ceralasertib may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for tumor cell growth. Giving biomarker selected personalized maintenance treatment with durvalumab, saruparib, ceralasertib or monalizumab may work better in treating patients with ES-SCLC.
Conditions
- Extensive Stage Lung Small Cell Carcinoma
- Lung Small Cell Carcinoma, A Subtype
- Lung Small Cell Carcinoma, I Subtype
- Lung Small Cell Carcinoma, N Subtype
- Lung Small Cell Carcinoma, P Subtype
Interventions
Biospecimen CollectionProcedure
Undergo tissue and blood sample collection
CeralasertibDrug
Given PO
Computed TomographyProcedure
Undergo CT scan
DurvalumabBiological
Given IV
EtoposideDrug
Given etoposide
Magnetic Resonance ImagingProcedure
Undergo MRI
MonalizumabBiological
Given IV
Platinum CompoundDrug
Given platinum compound
Positron Emission TomographyProcedure
Undergo PET/CT scan
SaruparibDrug
Given PO
Thoracic Radiation TherapyRadiation
Undergo thoracic radiation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Screen success rate (Screening)Time frame: Up to 3 years
- Progression-free survival (PFS) (Cohort A)Time frame: From date of randomization to treatment within a cohort to date of first documentation of progression, symptomatic deterioration, or death due to any cause, assessed up to 3 years
- PFS (Cohort B)Time frame: From date of randomization to treatment within a cohort to date of first documentation of progression, symptomatic deterioration, or death due to any cause, assessed up to 3 years
- PFS (Cohort C)Time frame: From date of randomization to treatment within a cohort to date of first documentation of progression, symptomatic deterioration, or death due to any cause, assessed up to 3 years
Locations
148 sites in 1 country. Site status is shown where the registry gives one.
Loma Linda University Medical Center
Loma Linda, California · Recruiting
Eisenhower Medical Center
Rancho Mirage, California · Recruiting
University of California Davis Comprehensive Cancer Center
Sacramento, California · Recruiting
UCHealth University of Colorado Hospital
Aurora, Colorado · Recruiting
UCHealth Memorial Hospital Central
Colorado Springs, Colorado · Recruiting
Memorial Hospital North
Colorado Springs, Colorado · Recruiting
Poudre Valley Hospital
Fort Collins, Colorado · Recruiting
Cancer Care and Hematology-Fort Collins
Fort Collins, Colorado · Recruiting
Lutheran Hospital - Cancer Centers of Colorado
Golden, Colorado · Recruiting
UCHealth Greeley Hospital
Greeley, Colorado · Recruiting
Medical Center of the Rockies
Loveland, Colorado · Recruiting
Smilow Cancer Hospital-Derby Care Center
Derby, Connecticut · Recruiting
Smilow Cancer Hospital Care Center-Fairfield
Fairfield, Connecticut · Recruiting
Smilow Cancer Hospital Care Center - Guilford
Guilford, Connecticut · Recruiting
Yale University
New Haven, Connecticut · Recruiting
Yale-New Haven Hospital North Haven Medical Center
North Haven, Connecticut · Recruiting
Smilow Cancer Hospital-Torrington Care Center
Torrington, Connecticut · Recruiting
Smilow Cancer Hospital Care Center-Trumbull
Trumbull, Connecticut · Recruiting
Smilow Cancer Hospital-Waterbury Care Center
Waterbury, Connecticut · Recruiting
Smilow Cancer Hospital Care Center - Waterford
Waterford, Connecticut · Recruiting
Helen F Graham Cancer Center
Newark, Delaware · Recruiting
Medical Oncology Hematology Consultants PA
Newark, Delaware · Recruiting
Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
Savannah, Georgia · Recruiting
Kootenai Health - Coeur d'Alene
Coeur d'Alene, Idaho · Recruiting
Saint Alphonsus Cancer Care Center-Nampa
Nampa, Idaho · Recruiting
Kootenai Clinic Cancer Services - Post Falls
Post Falls, Idaho · Recruiting
Kootenai Clinic Cancer Services - Sandpoint
Sandpoint, Idaho · Recruiting
Northwestern University
Chicago, Illinois · Recruiting
Northwestern Medicine Cancer Center Kishwaukee
DeKalb, Illinois · Recruiting
Northwestern Medicine Cancer Center Delnor
Geneva, Illinois · Recruiting
Northwestern Medicine Glenview Outpatient Center
Glenview, Illinois · Recruiting
Northwestern Medicine Grayslake Outpatient Center
Grayslake, Illinois · Recruiting
Northwestern Medicine Lake Forest Hospital
Lake Forest, Illinois · Recruiting
Loyola University Medical Center
Maywood, Illinois · Recruiting
Northwestern Medicine Oak Brook
Oak Brook, Illinois · Recruiting
Northwestern Medicine Orland Park
Orland Park, Illinois · Recruiting
Northwestern Medicine Cancer Center Warrenville
Warrenville, Illinois · Recruiting
Mary Greeley Medical Center
Ames, Iowa · Recruiting
McFarland Clinic - Ames
Ames, Iowa · Recruiting
UI Health Care Mission Cancer and Blood - Ankeny Clinic
Ankeny, Iowa · Recruiting
Showing 40 of 148 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.